564 related articles for article (PubMed ID: 32745604)
1. Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Sharifkashani S; Bafrani MA; Khaboushan AS; Pirzadeh M; Kheirandish A; Yavarpour Bali H; Hessami A; Saghazadeh A; Rezaei N
Eur J Pharmacol; 2020 Oct; 884():173455. PubMed ID: 32745604
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Datta PK; Liu F; Fischer T; Rappaport J; Qin X
Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005
[TBL] [Abstract][Full Text] [Related]
3. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
Nicolau LAD; Nolêto IRSG; Medeiros JVR
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
[No Abstract] [Full Text] [Related]
4. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
5. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
7. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.
Yang J; Petitjean SJL; Koehler M; Zhang Q; Dumitru AC; Chen W; Derclaye S; Vincent SP; Soumillion P; Alsteens D
Nat Commun; 2020 Sep; 11(1):4541. PubMed ID: 32917884
[TBL] [Abstract][Full Text] [Related]
8. Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins.
Anand SP; Chen Y; Prévost J; Gasser R; Beaudoin-Bussières G; Abrams CF; Pazgier M; Finzi A
Viruses; 2020 Sep; 12(10):. PubMed ID: 33003587
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
Ali A; Vijayan R
Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
[TBL] [Abstract][Full Text] [Related]
10. The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Offringa A; Montijn R; Singh S; Paul M; Pinto YM; Pinto-Sietsma SJ
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):317-325. PubMed ID: 32464637
[TBL] [Abstract][Full Text] [Related]
11. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
12. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication.
Pang X; Cui Y; Zhu Y
Acta Pharmacol Sin; 2020 Sep; 41(9):1255-1257. PubMed ID: 32581256
[No Abstract] [Full Text] [Related]
15. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
16. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
17. Structural basis of receptor recognition by SARS-CoV-2.
Shang J; Ye G; Shi K; Wan Y; Luo C; Aihara H; Geng Q; Auerbach A; Li F
Nature; 2020 May; 581(7807):221-224. PubMed ID: 32225175
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2.
Mittal A; Manjunath K; Ranjan RK; Kaushik S; Kumar S; Verma V
PLoS Pathog; 2020 Aug; 16(8):e1008762. PubMed ID: 32822426
[TBL] [Abstract][Full Text] [Related]
19. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Young MJ; Clyne CD; Chapman KE
J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.
Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY
Circ Res; 2020 May; 126(10):1456-1474. PubMed ID: 32264791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]